+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Membrane Flux Not Biocompatibility Determines Beta-2-Microglobulin Levels in Hemodialysis Patients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Serum β<sub>2</sub>-microglobulin (β<sub>2</sub>M) levels are important in dialysis-related amyloid deposition but can be influenced by dialysis technique. Methods: We measured β<sub>2</sub>M levels in 3 centres using different dialysis regimes. Centre 1 (73 patients) used high-flux biocompatible, centre 2 (72 patients) low-flux biocompatible and centre 3 (142 patients) cuprophane dialysers. Results: β<sub>2</sub>M levels were lower with high-flux biocompatible than with low-flux biocompatible or cuprophane dialysis (22.3 ± 5.4 vs. 43.4 ±13.7 and 37.6 ±13.1 mg/l, respectively; p < 0.001). Levels were higher with low-flux biocompatible than with cuprophane dialysis (p < 0.001), but not if patients dialysed over 10 years were excluded. With low-flux biocompatible (47.4 ± 9.8 vs. 38.7 ± 15.2 mg/l; p < 0.01) and cuprophane dialysis (43.4 ± 8.2 vs. 36.7 ± 13.0 mg/l; p < 0.02), β<sub>2</sub>M levels were higher in patients dialysed over 5 years than in those dialysed less. Despite β<sub>2</sub>M levels increasing as residual renal function declined, there was no similar rise with high-flux biocompatible dialysis. Conclusions: Techniques allowing significant convection maintain lower β<sub>2</sub>M levels over many years. Membrane flux, not biocompatibility, is the main determinant of β<sub>2</sub>M levels in routine practice.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          30 January 2002
          : 20
          : 2
          : 161-166
          aDirectorate of Medicine, Gloucestershire Royal Hospital, Gloucester; bRenal Unit, Lister Hospital, Stevenage; cRenal and Transplant Unit, St Mary’s Hospital, London, and dCentre for Nephrology, Royal Free Hospital, London, UK
          47003 Blood Purif 2002;20:161–166
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 2, Tables: 1, References: 31, Pages: 6
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/47003
          Original Paper


          Comment on this article